Clinical Trial Update: A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study of voxelotor (GBT440) 300 mg capsules in healthy subjects to assess single-dose relative bioavailability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Oxbryta (voxelotor)

Snippet

Sponsor: Global Blood Therapeutics | Conditions: Sickle Cell Disease | Phase 1 | Status: COMPLETED